Rtw Investments Adds $2M in Stoke Therapeutics, Inc. ($STOK)
RTW Investments added 76,669 shares of STOK, boosting its holdings to over 5.6 million shares.
Key Points
- RTW Investments increased its STOK position by 76,669 shares, reaching a total of 5,623,525 shares valued at $167.7 million.
- STOK shares traded around $29.82 with recent insider buying involving several executives acquiring 17,786 shares each.
- Analysts maintain a positive outlook on STOK, with multiple firms setting price targets between $35 and $60.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
RTW Investments has increased its stake in STOK, adding 76,669 shares to its holdings. This brings the total to 5,623,525 shares, valued at approximately $167.7 million, according to its most recent 13F filing. The filing reflects the fund's position as of the reporting period, which may not represent its current holdings.
What Changed in RTW Investments' STOK Position
RTW Investments boosted its stake in STOK by 76,669 shares, a change of about 1.4%. The fund now holds 5,623,525 shares in total. This increase suggests a continued interest in the company, with the position valued at $167.7 million based on the latest filing.
Other Institutional Activity in STOK
Several other institutional investors have also adjusted their positions in STOK. BlackRock, Inc. increased its holdings by 173,160 shares, now owning 5,385,714 shares valued at about $175.4 million. Meanwhile, FMR LLC reduced its stake by 217,254 shares, leaving it with 5,383,666 shares worth approximately $175.3 million. Redmile Group, LLC added 130,050 shares, resulting in a total of 4,164,120 shares valued at $135.6 million. Conversely, Lynx1 Capital Management LP cut its position by 641,001 shares, holding 4,763,673 shares valued at $155.1 million.
Stoke Therapeutics, Inc. Stock Down 5.7%
Shares of STOK traded around $29.82 recently. The company has experienced varying institutional interest, as seen in the recent 13F filings. STOK's market activity continues to be closely watched by investors and analysts alike.
Insider Buying and Selling at Stoke Therapeutics, Inc.
On June 3, 2026, several insiders, including Arthur Levin, Seth Loring Harrison, Edward MD Kaye, Arthur Tzianabos, Julie Smith, and Adrian Krainer, each purchased 17,786 shares of STOK. These transactions were not part of a pre-planned trading program.
Analysts Set New Price Targets
Analysts have maintained a positive stance on STOK, with several firms reiterating their buy ratings. On March 20, 2026, Canaccord Genuity maintained its buy rating with a price target of $60. BTIG reiterated a buy rating with a $39 target on March 19. Chardan Capital also maintained its buy rating, setting a target at $35 on March 18. Overall, the consensus among analysts remains favorable, with price targets ranging from $35 to $60.
Bottom Line
RTW Investments' increased stake in STOK highlights its confidence in the company, as reflected in its latest 13F filing. Investors often track such filings to gauge institutional sentiment, though they represent historical positions. The company's recent insider activity and strong analyst ratings suggest continued interest and potential growth prospects.
Get Stoke Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $STOK, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.